Viral Genetics, Inc. Provides Update on Phase 3 Trial of VGV-1 in South Africa

Treatment Stage of HIV/AIDS Study Completed Follow Up Stage to Conclude in Late 2005

AZUSA, Calif., July 21, 2005 (PRIMEZONE) -- Viral Genetics, Inc. (OTCBB:VRAL), a drug development company developing a biologic therapy for HIV infection, today announced that the eight-week, sixteen-injection treatment phase of the ongoing South African study is completed for all enrolled patients.

The phase 3 study of VGV-1 is examining Stage CDC-2 (the stage before full-blown AIDS) HIV-infected patients treated with VGV-1. This seven-center, randomized, double blind, placebo-controlled study of 137 patients is designed to monitor the safety, efficacy and immunological function of VGV-1. An interim safety analysis will be conducted in August as originally scheduled, and the follow-up phase will conclude in late 2005 with results expected in early 2006.

Quintiles is responsible for data management for the trial, and Dr. Jimmy Hwang of UC San Francisco will perform the data analysis.

About Viral Genetics, Inc.

Viral Genetics, Inc. is a drug discovery and development company based in Southern California developing treatments for infectious disease, autoimmune disease and immunological deficiency through its patented Thymus Nuclear Protein compound. For more information, visit

This news release contains forward-looking statements that involve risks and uncertainties associated with clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports with the Securities and Exchange Commission. VGV-1 and TNP are not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Viral Genetics, Inc. believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including the ability of Viral Genetics, Inc., to obtain adequate financing sufficient to meet its business objectives on reasonable terms and conditions, and therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by the Company or any other person that the objectives and plans of the Company will be achieved.


Contact Data